PFIC Space Hots Up With Albireo and Mirum Filings
Promising Therapies For Rare Liver Disease
Patients with the rare condition progressive familial intrahepatic cholestasis (PFIC) look set to have two possible therapeutic choices if recent filings for two IBAT inhibitors are successful.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.